AlloVir (ALVR) said Friday it signed a definitive agreement to merge with Kalaris Therapeutics (KLRS) in an all-stock transaction.
The combined company will take on the name of Kalaris Therapeutics and is expected to trade on Nasdaq under the ticker symbol "KLRS," AlloVir said.
It will have around $100 million in cash upon closing, AlloVir said, adding that the cash is expected to fund the combined company's operations through Q4 of 2026.
AlloVir will acquire all of Kalaris' outstanding equity interest and said its shareholders will own around 25% of the combined company when the transaction closes, while shareholders of pre-merger Kalaris will own roughly 75%.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。